A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma
Top Cited Papers
- 15 January 2008
- journal article
- research article
- Published by American Society of Hematology in Blood
- Vol. 111 (2), 558-565
- https://doi.org/10.1182/blood-2007-06-095331
Abstract
There is no generally established prognostic index for patients with mantle cell lymphoma (MCL), because the International Prognostic Index (IPI) and Follicular Lymphoma International Prognostic Index (FLIPI) have been developed for diffuse large cell and follicular lymphoma patients, respectively. Using data of 455 advanced stage MCL patients treated within 3 clinical trials, we examined the prognostic relevance of IPI and FLIPI and derived a new prognostic index (MCL international prognostic index, MIPI) of overall survival (OS). Statistical methods included Kaplan-Meier estimates and the log-rank test for evaluating IPI and FLIPI and multiple Cox regression for developing the MIPI. IPI and FLIPI showed poor separation of survival curves. According to the MIPI, patients were classified into low risk (44% of patients, median OS not reached), intermediate risk (35%, 51 months), and high risk groups (21%, 29 months), based on the 4 independent prognostic factors: age, performance status, lactate dehydrogenase (LDH), and leukocyte count. Cell proliferation (Ki-67) was exploratively analyzed as an important biologic marker and showed strong additional prognostic relevance. The MIPI is the first prognostic index particularly suited for MCL patients and may serve as an important tool to facilitate risk-adapted treatment decisions in patients with advanced stage MCL.Keywords
This publication has 33 references indexed in Scilit:
- Mantle cell lymphoma: prognostic capacity of the Follicular Lymphoma International Prognostic IndexBritish Journal of Haematology, 2006
- Histopathology, cell proliferation indices and clinical outcome in 304 patients with mantle cell lymphoma (MCL): a clinicopathological study from the European MCL NetworkBritish Journal of Haematology, 2005
- Early consolidation by myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission significantly prolongs progression-free survival in mantle-cell lymphoma: results of a prospective randomized trial of the European MCL NetworkPublished by American Society of Hematology ,2005
- Long-term follow-up of autologous stem cell transplantation in patients with diffuse mantle cell lymphoma in first disease remissionCancer, 2003
- A Danish population-based analysis of 105 mantle cell lymphoma patientsEuropean Journal Of Cancer, 2002
- Mantle cell lymphoma. A clinicopathologic study of 68 cases from the Nebraska Lymphoma Study GroupAmerican Journal of Hematology, 2000
- Proportional hazards tests and diagnostics based on weighted residualsBiometrika, 1994
- Dangers of Using "Optimal" Cutpoints in the Evaluation of Prognostic FactorsJNCI Journal of the National Cancer Institute, 1994
- Martingale-based residuals for survival modelsBiometrika, 1990
- Partial residuals for the proportional hazards regression modelBiometrika, 1982